{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-030839","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2021-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.393863+00:00","generated_at":"2026-06-28T02:50:05.703591+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Biotricity CEO letter cites record Q2 revenue of $1.81M (+143% YoY), sets 2022 goals","bullets":["Record quarterly revenue of $1.81M for Q2 FY2022 ended Sep 30, 2021, up 143% YoY, tenth consecutive triple-digit growth quarter.","Recent uplisting to Nasdaq to attract larger investor pool and increase liquidity.","Introduced Biokit, a 3-device personal medical kit for integration into Biotricity ecosystem.","Product roadmap includes Bioflux, Biotres, Biocare Telemed, and Bioheart.","2022 goals: launch new cardiac monitoring solutions and software services to become turnkey cardiac health provider."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-030839","json":"https://secwatch.observer/filing/0001493152-21-030839.json","markdown":"https://secwatch.observer/filing/0001493152-21-030839.md","text":"https://secwatch.observer/filing/0001493152-21-030839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315221030839/0001493152-21-030839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315221030839/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T02:50:05.703591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}